Commentary: innovation policy for a new era

J Law Med Ethics. 2009 Summer;37(2):264-8. doi: 10.1111/j.1748-720X.2009.00370.x.

Abstract

This commentary offers a response to the Sonderholm, Bird, and Flynn et al. articles, and argues that the current innovation crisis requires more ambitious approaches, as well as a serious consideration of alternative mechanisms for R&D such as prizes.

Publication types

  • Comment

MeSH terms

  • Anti-Bacterial Agents / supply & distribution*
  • Developing Countries
  • Drug Discovery / economics*
  • Drug Discovery / legislation & jurisprudence
  • Drug Industry / economics
  • Drug Industry / ethics
  • Drug Industry / legislation & jurisprudence
  • Drug Resistance, Microbial
  • Drug and Narcotic Control / legislation & jurisprudence*
  • Health Services Accessibility* / economics
  • Health Services Accessibility* / legislation & jurisprudence
  • Humans
  • Patents as Topic / legislation & jurisprudence*

Substances

  • Anti-Bacterial Agents